Welcome Guest to Happi

Subscribe Free: Magazine | eNewsletter

current issue July 2014
 •  Pilot Launches New Site  •  Nu Skin Marks 30th Anniversary  •  Eileen Ford, Dead at 92  •  Birchbox Goes Brick-and-Mortar  •  Galderma Gains Full Rights To Distribute Restylane
Print

11. GlaxoSmithKline



Published August 6, 2012
Related Searches: health management marketing sales
11. GlaxoSmithKline
United Kingdom
www.gsk.com

Sales: $2.7 billion

Key Personnel: Andrew Witty, chief executive officer; Simon Dingemans, chief financial officer; Emma Walmsley, president, consumer healthcare worldwide.

Major Products: Oral care—Aquafresh, Biotene, Dr Best, Macleans, Odol and Sensodyne; Denture care—Polident, Poligrip and Corega.

New Products: Sensodyne Repair & Protect.

Comments: GSK is one of the world’s leading pharmaceutical companies with corporate sales of nearly $44 billion last year.

Oral care product sales rose 8% last year, due in large part to the success of the Sensodyne brand, which grew 16%, driven by the launch of Sensodyne Repair & Protect, and the brand’s ongoing roll-out in emerging markets. Denture care sales were up, thanks to double-digit gains in emerging markets, as well as growth in Japan and the US, according to the firm.

In October, 2011, Emma Walmsley was named president, consumer healthcare worldwide. She had been president of consumer health care, Europe. Walmsley joined GSK from L’Oréal where she worked for 17 years, holding a variety of marketing and general management roles in Paris, London and New York.

To keep growing in 2012, GlaxoSmithKline has refocused its consumer healthcare portfolio into four, large, high-value categories: wellness, oral health, nutrition and skin health. The company’s goal is to become the world’s most successful fast-moving consumer healthcare company, driven by science and values.

To help get there, in January, GSK sold several non-core brands to Prestige Brands Holdings for about $680 million. The brands, including BC, Goody’s, Beano, Ecotrin, FiberChoice and Tagamet, had sales of approximately $200 million in 2011.

For the first quarter of 2012, consumer health care sales rose 1%, driven by an 11% gain in oral care sales, which reached $739 million. The company noted that Sensodyne registered its 12th consecutive quarter of double-digit growth.

 


blog comments powered by Disqus